9.12.01: Bear, Stearns & Company 14th Annual Healthcare Conference Issue
Eight analysts and top management from ninety-five sector firms examine the Healthcare sector in this special 352-page Bear, Stearns & Company 14th Annual Healthcare Conference issue from The Wall Street Transcript.

    Online subscribers to the Technology sector also get
    The Lehman Brothers Semiconductor and Computer Systems Conference Issue & Electronic Supply Chain Issue

  1. Investing in Health Care - In an in-depth (2,200 words) Analyst Interview, Joseph Riccardo, Managing Director at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  2. Medical Information Management - In an in-depth (4,700 words) Analyst Interview, Raymond Falci, Senior Managing Director at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  3. US Pharmaceutical Companies - In an in-depth (2,200 words) Analyst Interview, Scott Shevick, Senior Managing Director covering the major pharmaceuticals sector of the healthcare industry at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  4. Biotechnology Stocks - In an in-depth (1,100 words) Analyst Interview, Akhtar Samad, Managing Director at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  5. Pharmaceutical Stocks - In an in-depth (2,100 words) Analyst Interview, Frederick Wise, Managing Director at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  6. Large Cap Biotechnology Stocks - In an in-depth (1,300 words) Analyst Interview, Ronald Renaud, Associate Director at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  7. Managed Care/Health Benefits - In an in-depth (1,600 words) Analyst Interview, John Rex, Senior Research Analyst at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  8. Pharmaceutical Services - In an in-depth (2,400 words) Analyst Interview, Stephen Unger, Equity Research Analyst at Bear, Stearns & Co., examines the outlook for the sector and shares specific stock recommendations.
  9. CEO interviews (average 2,500 words). Top management of ninety-five sector firms examine the outlook for their firm and the sector. Firms include:
    Active Health Management, Inc., Aetna, Alexion Pharmaceuticals, ALTANA AG, Anadys Pharmaceuticals, Andrx, Applied BioSystems Group, AstraZeneca, athenahealth, Basilea Pharmaceutica, Baxter International, Beckman Coulter, Biomet, Boron, LePore & Associates, Bruker Daltonics, Caliper Technologies, Caprion Pharmaceuticals, Cerner, CIGNA, Coley Pharmaceutical Group, Collateral Therapeutics, Cubist Pharmaceuticals, CuraGen, D&K Healthcare Resources, Dendrite International, Diversa, Edward Lifesciences, Elitra Pharmaceuticals, Entelos, Exelixis, First Health Group, Genaissance Pharmaceuticals, Genitope, Genzyme Biosurgery, HCA, Health Net, HEALTHSOUTH, Human Genome Sciences, ICON, ICOS, IDEXX Laboratories, Inspire Pharmaceuticals, Integra LifeSciences Holdings, Integrative Proteomics, Integrity Pharmaceutical, Intuitive Surgical, Inveresk Research International, Large Scale Biology, Lexicon Genetics, Ligand Pharmaceuticals, Magellan Health Services, Maret, McKesson, Medarex, Medsite.com, Medsource Technologies, Memory Pharmaceuticals, Metrika, MicroMed Technology, NDCHealth, NicOx S.A., Novartis Pharmaceuticals Corp. - USA, Novirio Pharmaceuticals, OSI Pharmaceuticals, Oxford Health Plans, PAREXEL International, Phase Forward, Phylos, Qiagen, N.V., Raven Biotech, Renal Care Group, RenalTech International, RightCHOICE Managed Care, Shire Pharmaceuticals Group, Sierra Health Services, Songbird Hearing, Spotfire, Structural GenomiX, Synaptic Pharmaceutical, SYNAVANT, Syrrx, Tanox, TechRx, Telik, Thoratec, Transgenomic, TransVascular, Triad Hospitals, Trigon Healthcare, Trimeris, TriZetto Group, Ventana Medical Systems, Xencor, Xenon Genetics, X-Mine
    10. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE